A recent study conducted in Turkey has shed light on the remarkable efficiency improvements and advancements in early cancer detection facilitated by Lunit INSIGHT MMG, an AI-powered mammography analysis solution developed by Lunit, a leading provider of AI-driven solutions for cancer diagnostics and therapeutics.
Published in the prestigious European Radiology journal, the study, conducted in collaboration with researchers from several Turkish universities including Acibadem Mehmet Ali Aydinlar University, Marmara University, Namik Kemal University, and Istanbul University, examined the effectiveness of Lunit INSIGHT MMG in breast cancer detection within a screening program.
The comprehensive study analyzed over 22,621 mammograms from 8,825 women over a decade. Leveraging Lunit INSIGHT MMG, the researchers aimed to evaluate its capability in early cancer detection and reducing the workload of radiologists.
A key finding of the study was the potential of Lunit INSIGHT MMG to decrease radiologists’ workload by nearly 70% through a hybrid workflow scenario, where mammograms were categorized into immediate review, further evaluation, or no action needed based on AI-assessed risk scores. Additionally, the solution demonstrated a 30.5% increase in cancer detection accuracy, marking a significant advancement in breast cancer screening efficiency and potentially enabling broader screening coverage.
The study also highlighted the AI system’s ability to identify 51.72% of interval cancers and 50% of missed cancers, underscoring its effectiveness in detecting cancers that may have been overlooked in traditional screening methods. Furthermore, using Lunit INSIGHT MMG as a second reader could potentially expedite diagnosis by an average of nearly 30 months compared to conventional methods.
Brandon Suh, CEO of Lunit, emphasized the dual benefits of AI in medical diagnostics, not only in enhancing medical outcomes but also in streamlining workflows and reducing healthcare costs. He highlighted the importance of further integrating AI to maximize the quality of care and the sustainability of healthcare systems.
Lunit, founded in 2013, is dedicated to leveraging AI to ensure accurate diagnosis and optimal treatment for cancer patients. With FDA clearance and the CE Mark, its flagship Lunit INSIGHT suite is currently used in approximately 3,000+ hospitals and medical institutions across 40+ countries. Headquartered in Seoul, South Korea, Lunit has a global presence with offices and representatives worldwide.
Source: Lunit
Radiology AI 
Leave a comment